Division of Daiichi Sankyo Co. Ltd.
Latest From Plexxikon Inc.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.
Further progress for Daiichi Sankyo's strategic push into oncology as US issues first approval globally for first-in-class rare disease drug Turalio - but with liver toxicity safeguards.
Daiichi Sankyo denies report it is in negotiations to sell its OTC business, but might such a move actually align well with mid-term strategy?
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Daiichi Sankyo Co. Ltd.
- Senior Management
K. Peter Hirth, PhD, CEO
Kathleen Sereda Glaub, Pres.
Gideon E Bollag, PhD, SVP, Research
- Contact Info
Phone: (510) 647-4000
91 Bolivar Dr.
Berkeley, CA 94710
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.